EyePoint Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Attached files

file	filename
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) - EyePoint Pharmaceuticals, Inc.	dex311.htm
EX-21.1 - SUBSIDIARIES OF PSIVIDA CORP. - EyePoint Pharmaceuticals, Inc.	dex211.htm
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - EyePoint Pharmaceuticals, Inc.	dex322.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) - EyePoint Pharmaceuticals, Inc.	dex312.htm
10-K - FORM 10-K - EyePoint Pharmaceuticals, Inc.	d10k.htm
EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 - EyePoint Pharmaceuticals, Inc.	dex321.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement Nos. 333-152146 and 333-163208 on Form S-8 and Registration Statement Nos. 333-132777, 333-141083, 333-143225, 333-163347 and 333-163349 on Form S-3 of our report dated September 27, 2010, relating to the financial statements of pSivida Corp. appearing in this Annual Report on Form 10-K of pSivida Corp. for the year ended June 30, 2010.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

September 27, 2010

Attached files

Stock widget

Investing forum

EyePoint Pharmaceuticals, Inc. Reports